| Publication Abstract Display | | Type: Poster | | Title: Lower than expected Maraviroc concentrations in cerebrospinal fluid still exceed the 50% inhibitory concentration for wild-type CCR5-tropic HIV-1. | | Authors: Croteau D, Best B, Letendre S, Rossi S, Ellis RJ, Clifford D, Collier A, Gelman B, Marra C, McArthur J, McCutchan JA, Morgello S, Simpson D, Way L, Capparelli E, Grant I | | Date: 10-12-2010 | | Abstract:HIV-associated neurocognitive disorders remain very common complications of HIV infection despite the broad use of very active antiretrovirals (ARVs) (Heaton 2010)
ARVs achieving higher concentrations in cerebrospinal fluid (CSF) are associated with HIV suppression in CSF and better neurocognitive performance (Letendre 2004)
MVC is the first drug in the new class of fusion inhibitors blocking the chemokine (C-C motif) receptor 5 (CCR5), a co-receptor critical for cellular entry of R5-tropic viruses (Kromdijk 2010)
CCR5 is the major co-receptor used for entry into macrophages in the peripheral immune system and into microglia, an important virion-producing source in the CNS (Albright 1999) |
return to publications listing
|